Continuous Liposomal API Diafiltration for Commercial Scale-Up
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of reliable manufacturing methods for liposomal active pharmaceutical ingredients (APIs) with sufficient throughput to enable commercial scale-up, limiting the application of liposomal products in pharmaceutical development.
Innovation Solution
A continuous manufacturing process is employed for liposomal APIs, involving the mixing of lipid and aqueous API solutions in an in-line fashion to form liposomal encapsulated APIs, followed by tangential flow filtration (TFF) for continuous in-line diafiltration, allowing for the formation and refinement of liposomal API formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If batch processing methods are used for liposomal drug manufacture, then manufacturing flexibility and product quality control are maintained, but production time and cost increase significantly
Solution Approach 1:
The manufacturing process is divided into distinct modular units: a liposome formation unit, a drug incorporation unit, and a purification unit. Each unit performs a specific function independently, allowing continuous operation while maintaining quality control through segmented process control.
Solution Approach 2:
The patent implements continuous manufacturing where liposomes are formed, drug is incorporated, and purification occurs in an uninterrupted flow process. The system maintains continuous operation through fed-batch addition of materials and continuous passage through extrusion devices, eliminating the stop-start nature of batch processing.
2Manufacturing precision
If conventional batch methods are used, then process simplicity is maintained, but manufacturing precision and product consistency deteriorate
Solution Approach 1:
The system incorporates real-time monitoring and feedback control at critical process points, including material addition rates, extrusion parameters, and purification efficiency. This allows dynamic adjustment to maintain consistent product quality while managing the complexity of the continuous system.
Solution Approach 2:
The patent utilizes controlled parameter changes throughout the continuous process, including temperature, pressure, flow rates, and material concentrations. These parameters are optimized and maintained within specific ranges to ensure product consistency while enabling continuous operation.
3Productivity
If continuous manufacturing is implemented, then production efficiency and cost reduction are achieved, but process control and quality monitoring become more difficult
Solution Approach 1:
The patent introduces intermediary substances and control mechanisms that facilitate monitoring and control of the continuous process. These include process analytics tools, sampling systems, and control agents that enable real-time detection and measurement without disrupting the continuous flow.
Solution Approach 2:
The system replaces manual batch monitoring with automated sensing and measurement technologies. This includes optical sensors, flow meters, and other analytical instruments that continuously monitor process parameters, reducing the difficulty of detection and measurement in the continuous regime.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables efficient and consistent production of liposomal APIs with improved quality and reduced costs, offering economic advantages and a smaller facility footprint.
Implementation Method 1
The liposome formulation is extruded through a device that causes the liposome formulation to pass through a membrane
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are methods for making liposomal API formulations via continuous in-line diafiltration processes. Also provided herein are liposomal API formulations manufactured by the disclosed methods.